A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

NCT01936688 ↗

Phase 3 Withdrawn Sun Pharmaceutical Industries, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.

Timeline

Start: 2013-09
Primary completion: 2018-08
Completion: 2018-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous
Subject	Tildrakizumab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Tildrakizumab	Monoclonal antibody	200 mg	Subcutaneous

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Summary

Timeline

Drugs

Indications